Update shared on 12 Nov 2025
Analysts have increased their price target for ADMA Biologics to $27.25. They cite expectations for stronger revenue growth and higher profit margins, balanced against a slightly higher discount rate and declining future price-to-earnings multiples.
What's in the News
- ADMA Biologics completed a buyback of 512,411 shares for $8.03 million between July 1, 2025 and September 30, 2025. This brings the total repurchased to 1,328,648 shares for $23.01 million under the current program.
- The company raised its earnings guidance for fiscal years 2025 and 2026. It now expects at least $510 million in total revenue for 2025 and at least $630 million for 2026, up from previous forecasts.
- ADMA Biologics provided new earnings guidance for fiscal year 2029, targeting total annual revenue of $1.1 billion or more and anticipating substantial earnings growth with strong operational momentum. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target remains unchanged at $27.25 per share.
- Discount Rate increased slightly from 6.88% to 7.02%.
- Revenue Growth expectation has risen modestly, with an increase from 23.50% to 24.38%.
- Net Profit Margin was revised upward from 39.32% to 41.14%.
- Future P/E has decreased, declining from 23.21x to 20.90x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.